VIP (Vasoactive Intestinal Peptide)
Endogenous neuropeptide. Regulates the immune response (Th1/Th2), reduces inflammatory cytokines and improves cerebral and pulmonary blood flow. Crucial in the Shoemaker protocol.
- Treatment of Biotoxin Illness (Mould)
- Reduction of systemic inflammation
- Hormonal regulation (Pituitary)
- Respiratory improvementTreatment of Biotoxin Illness (Mould)
- Respiratory improvement
- Drop in blood pressure (hypotension).
- Pancreatitis (high doses).
- Palpitations.Drop in blood pressure (hypotension).
- Palpitations.
VIP is an endogenous neuropeptide of 28 amino acids that acts as a potent vasodilator and immune regulator, influencing the neuro-immune-endocrine axis on multiple levels.
READ MORE
What it is (in plain language)
- VIP is like a 'pacifier' for the immune system. It helps open up the blood vessels (lowering lung pressure) and regulates the inflammatory response in the brain and lungs. It is essential for maintaining the circadian rhythm and for preventing the body from attacking its own tissues in situations of extreme inflammatory stress.
Why do you appear online so much
- It is the cornerstone of the treatment protocol for CIRS (Chronic Inflammatory Response Syndrome) caused by mould or biotoxins. People with chronic brain fog and chemical sensitivities find VIP a tool for restoring levels of regulatory hormones such as MSH and lowering inflammation in the hypothalamus.
How it is framed today (pragmatic view)
- 1) Evidence: Clinical use established in specific functional medicine protocols and for pulmonary hypertension. 2) Objective: Recovery of sensitivity to biotoxins, hormonal regulation and immune modulation. 3) Risk: Should only be used after removing the source of exposure (e.g. mould) and under blood pressure monitoring.
How to use this form
- Read the section on CIRS and circadian rhythm regulation carefully to maximise the therapeutic benefits.
- Quick profile (curated by Subject 157)
- Class: Immune
- Status: Verified
- Use case: Wellness
- Route: Nasal
- Tags: Nasal|Immune|CIRS
- Half-life: <2 Mins (Blood)
- Start: Immediate
- Duration: Short
- Mechanism (high level)
Endogenous neuropeptide. Regulates the immune response (Th1/Th2), reduces inflammatory cytokines and improves cerebral and pulmonary blood flow. Crucial in the Shoemaker protocol.
- Evidence (what the literature covers)
RANGE OF RESEARCH (Clinical/Functional, Non-prescriptive):
Shoemaker Protocol (Nasal).
Level of Evidence: B.
- Safety and harm-reduction (non-prescriptive)
Risks: Drop in blood pressure (hypotension).
Pancreatitis (high doses).
Palpitations.
Interactions: Antihypertensives.
- References (anchors)
- Shoemaker, R. C. (2005) - WDB biotoxin illness time-series study - https://doi.org/10.1016/j.ntt.2004.07.005 | PubMed:15681119
- Shoemaker, R. C. (2013) - Chronic Inflammatory Response Syndrome: Diagnosis & Treatment - https://doi.org/10.4236/health.2013.53053
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL